A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG–PEI–cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian,fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study 期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG–PEI–cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian,fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study

摘要：
收稿时间：	2014-02-05
本文献已被 ScienceDirect 等数据库收录！